{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Dose reduction to 720mg twice daily"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Dose reduction to 480mg twice daily"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Dose reduction to 240mg twice daily"},{"measurements":[{"groupId":"OG000","value":"23"}],"title":"Did not need a dose reduction"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Toxicity will be graded and recorded using the NCI Common Toxicology Criteria version 4.0.","groups":[{"description":"Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).","id":"OG000","title":"Vemurafenib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Toxicity (Safety and Tolerability)","type":"SECONDARY","unitOfMeasure":"Participants"}